Related Experiment Video
Updated: Apr 17, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Long-term data from the Swiss pulmonary hypertension registry
Séverine Mueller-Mottet1, Hans Stricker, Guido Domenighetti
1Pulmonary Clinic, University Hospital Zurich, Zurich, Switzerland.
Long-term data from the Swiss Pulmonary Hypertension (PH) registry shows improved survival for pulmonary arterial hypertension (PAH) and chronic thromboembolic PH (CTEPH) patients diagnosed more recently. Treatments have advanced, with increased use of targeted therapies.
Area of Science:
- Cardiology
- Pulmonology
- Epidemiology
Background:
- Registries are crucial for real-world epidemiological studies of diverse pulmonary hypertension (PH) groups.
- The Swiss PH registry has collected data since 1998.
Purpose of the Study:
- To present long-term data from the Swiss PH registry spanning 1998-2012.
- To analyze trends in patient demographics, hemodynamics, and treatment over time.
Main Methods:
- PH patients were classified into five groups and registered with informed consent.
- Data collected included NYHA class, 6-minute walk distance, hemodynamics, and therapy.
- Patient data were stratified by diagnosis time: prevalent before 2000 and incident during 2000-2004, 2005-2008, and 2009-2012.
Main Results:
- The registry included 996 PH patients: 549 PAH, 36 PH-left heart disease, 127 PH-lung disease, 249 CTEPH, and 35 miscellaneous.
- Over time, patient age and BMI increased, while hemodynamic severity decreased.
- Event-free survival improved for PAH and CTEPH patients diagnosed since 2008, with increased use of targeted therapies.
Conclusions:
- Since 2000, incident Swiss PH patients were older, had better hemodynamics, and received more PAH target therapies.
- Survival rates have improved for PAH and CTEPH patients diagnosed in more recent periods.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

